Valneva (NASDAQ:VALN) Stock Price Down 5.6% – Should You Sell?

Valneva SE (NASDAQ:VALN)’s stock price traded down 5.6% during trading on Friday . The stock traded as low as $6.55 and last traded at $6.54. 19,989 shares traded hands during mid-day trading, a decline of 64% from the average session volume of 54,825 shares. The stock had previously closed at $6.93.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Valneva in a research report on Friday, January 31st.

Valneva Stock Performance

The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The business has a 50 day moving average of $4.52 and a 200 day moving average of $5.66. The company has a market capitalization of $526.97 million, a P/E ratio of -50.08 and a beta of 1.98.

Institutional Investors Weigh In On Valneva

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA purchased a new position in Valneva SE (NASDAQ:VALN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is owned by hedge funds and other institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.